Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer
December 13th 2024, 9:08pm
San Antonio Breast Cancer Symposium
Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer
Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC
December 13th 2024, 7:13pm
San Antonio Breast Cancer Symposium
Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.
Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff
December 13th 2024, 4:42pm
OncLive News Network: On Location at SABCS 2024
Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
December 13th 2024, 3:02pm
ASH Annual Meeting and Exposition
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
December 13th 2024, 3:10am
San Antonio Breast Cancer Symposium
Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
December 13th 2024, 2:20am
San Antonio Breast Cancer Symposium
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.
Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer
December 12th 2024, 10:30pm
San Antonio Breast Cancer Symposium
Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.
Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar
December 12th 2024, 9:31pm
OncLive News Network: On Location at SABCS 2024
Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
December 12th 2024, 6:43pm
San Antonio Breast Cancer Symposium
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
December 12th 2024, 5:56pm
San Antonio Breast Cancer Symposium
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
December 12th 2024, 5:00pm
San Antonio Breast Cancer Symposium
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
Optimizing Treatment Sequences Remains Key in CLL/SLL
December 12th 2024, 4:42pm
ASH Annual Meeting and Exposition
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia
December 12th 2024, 3:00pm
ASH Annual Meeting and Exposition
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
December 12th 2024, 2:05am
San Antonio Breast Cancer Symposium
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.
Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham
December 11th 2024, 11:48pm
OncLive News Network: On Location at SABCS 2024
Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
December 11th 2024, 10:05pm
ASH Annual Meeting and Exposition
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer
December 11th 2024, 9:29pm
San Antonio Breast Cancer Symposium
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
December 11th 2024, 9:13pm
San Antonio Breast Cancer Symposium
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.
SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer
December 11th 2024, 9:06pm
San Antonio Breast Cancer Symposium
SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.
Adjuvant Olaparib Maintains iDFS Benefit in BRCA1/2+, HER2– Breast Cancer
December 11th 2024, 8:54pm
San Antonio Breast Cancer Symposium
Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.